A phase i trial of SJG-136 (NSC#694501) in advanced solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Benzodiazepinones
  • Pyrroles

abstract

  • For patients with advanced solid tumors, the MTD of SJG-136 is 40 microg/m2/day administered on days 1, 8 and 15 of a 28-day cycle. The major dose limiting toxicity was fatigue. Alternative dosing strategies are now being evaluated.

publication date

  • April 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3711187

Digital Object Identifier (DOI)

  • 10.1007/s00280-009-1088-4

PubMed ID

  • 19672598

Additional Document Info

start page

  • 833

end page

  • 8

volume

  • 65

number

  • 5